Effect of changes in treatment practice on survival for cervical cancer: results from a population-based study in Manitoba, Canada by Yoon-Jung Kang et al.
RESEARCH ARTICLE Open Access
Effect of changes in treatment practice on
survival for cervical cancer: results from a
population-based study in Manitoba, Canada
Yoon-Jung Kang1,2*, Dianne L. O’Connell2, Robert Lotocki3,5, Erich V. Kliewer4,5, David E. Goldsbury2,
Alain A. Demers4,5 and Karen Canfell1,2
Abstract
Background: Results from clinical trials in the 1990s led to changes in the recommended treatment for the standard
therapy for stage IIB-IVA cervical cancer from radiotherapy alone to chemo-radiotherapy. We conducted the first
population-based study in Canada to investigate temporal treatment patterns for cervical cancer and long-term survival
in relation to these changes in the treatment guidelines.
Methods: Detailed information on stage and treatment for 1085 patients diagnosed with cervical cancer in 1984–2008
and identified from the population-based Manitoba Cancer Registry (MCR) in Canada was obtained from clinical chart
review and the MCR. Factors associated with receiving guideline treatment were identified using logistic regression. All
cause and cervical cancer specific survival were compared in patients who were and were not treated as recommended
in the guidelines, using Cox proportional hazards models.
Results: The median follow-up time was 6.4 years (range: 0.05–26.5 years). The proportion of women who received
guideline treatment was 79 % (95 % confidence interval [CI]: 76–81 %). However, the likelihood of being treated
according to the guidelines over time was modified by age (p< 0.0001) and tumour stage at diagnosis (p= 0.002).
Women who were treated according to the guidelines after the change in recommended clinical practice (1999–2008)
had a significantly lower risk of death from all causes and from cervical cancer. This was driven by lower mortality rates in
cases with stage IIB-IVA tumours (all causes of death: hazard ratio [HR] = 0.60, 95 % CI: 0.43–0.82, p = 0.002; cervical cancer
related death: HR = 0.64, 95 % CI: 0.44–0.93, p = 0.02).
Conclusions: The management of cervical cancer patients in Manitoba, Canada was in good agreement with treatment
guidelines although reasons for departure from the guideline recommendations could not be examined further due to
lack of data. Treatment of stage IIB-IVA cervical cancers with recommended concurrent chemo-radiotherapy, which is
now standard practice, was associated with substantially increased survival, although the effect of changes in clinical
practice including maintenance of haemoglobin levels on improved survival cannot be ruled out as a contributing factor.
Background
Until the 1990s the standard therapy for International
Federation of Gynecology and Obstetrics (FIGO) stage IIB-
IVA cervical cancer, or earlier stage disease with adverse
pathological features, involved radiation alone. However, a
rapid increase in concurrent use of chemo-radiotherapy has
occurred since the mid-1990s, after multi-centre rando-
mised controlled trials (RCTs) [1–3] found cisplatinum-
based concurrent chemo-radiotherapy prolonged survival
in patients with advanced cervical cancer compared to
radiotherapy alone. Subsequently, treatment guidelines in
many jurisdictions [4–7] incorporated this new evidence.
By contrast, the recommended treatments for early stage
disease (FIGO Stage I-IIA), consisting of surgery with or
without adjuvant radiotherapy, have not changed substan-
tially over the last few decades. In Canada, guidelines for
cervical cancer management have not been formulated at a
national level, but the available provincial guidelines in
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Ontario [8, 9] and British Columbia [10] do not sub-
stantially differ from the guidelines developed by the
FIGO [11, 12] or available guidelines in other countries
[4, 5, 7]. Therefore, “synthesised” guidelines, derived
from available Canadian provincial and international
guidelines, reflecting the available evidence can be
readily formulated for Manitoba.
Studies from two Canadian centres in Ontario have
investigated trends in the use of concurrent chemo-
radiotherapy and resulting improved survival outcomes in
cervical cancer patients, without adjusting for tumour stage
[13, 14]. However, a population-based study investigating
survival outcomes with long term follow up in women who
were and were not managed in concordance with treatment
guidelines has not previously been performed in the
Canadian setting. Therefore, the aims of this study
were to describe: 1) trends in treatment patterns in
relation to changes in guideline recommendations; 2)
the proportion of cervical cancer patients receiving treat-
ment as recommended in the guidelines; 3) factors related
to receiving treatment according to the guidelines; and 4)
the impact of adhering to guidelines on the risk of death
from all causes (i.e., any death) and from cervical cancer in
the Canadian province of Manitoba.
Methods
Study sample and data sources
The population-based Manitoba Cancer Registry (MCR)
was used to identify all incident cervical cancer cases diag-
nosed over the period 1984 to 2008 [15]. More detailed in-
formation on treatment was obtained by combining the
MCR and a database derived from chart reviews (available
only for the years 1984–1999); the registry and the charts
are both maintained by CancerCare Manitoba.
Treatment procedures were coded using ICD-9-CM
Volume 3 from 1984 to 2004 and the Canadian Classifica-
tion of Health Interventions from 2005 to 2008: these two
classification systems are comparable [16]. Morphologic
data were coded using ICD-O-2 (1984–2000) and ICD-O-3
(2001–2008) that were comparable to each other. Cause of
death was coded using ICD-9 until 1999 and ICD-10
thereafter. Although comparability between ICD-9 and
ICD-10 on cause of death could not be examined for
the current dataset, it was reported that there was a 2 %
increase in cervical cancer death when using ICD-10 com-
pared to using ICD-9 [17].
Information on patients’ performance status, comor-
bidities and recurrence were not recorded on either
clinical chart or the MCR. Disease stage was defined ac-
cording to the FIGO staging system (1984–1999) and
equivalent American Joint Committee on Cancer (AJCC)
staging system (2004–2008). For those who were diag-
nosed in 2000 to 2003, a stage based on the agreement
between FIGO stage and clinical TNM category was
used. This was based on the fact that the agreement
between FIGO stage and clinical TNM staging, using the
clinical chart review dataset that contains both staging
information, was substantial (kappa = 0.74, weighted
kappa = 0.83) [18]. The agreement between the two sta-
ging systems was relatively lower for patients with stage
IB2-IIA disease (68 %), but the proportions under-staged or
over-staged were similar (15 % vs 18 %, respectively).
During 1984 to 2008, a total of 1413 incident cases of
cervical cancer were identified from the MCR. For the
overlapping period 1984 to 1999, the reliability of the
two data sets was examined by comparing seven indica-
tors including the number of cases diagnosed in each
year, date of diagnosis, age at diagnosis, treatment proce-
dures and related dates, histology and cause of death.
During the period, the total number of patients identi-
fied from any of the two data sets was 1043. Of these,
845 (81 %) were found in both data sets, and the
remaining number of patients included 87 non-residents
in the clinical chart review and 111 residents in the clin-
ical cancer registry. For the 845 patients identified in
both data sets, there was full agreement for six out of
the seven indicators. The only exception was cause of
death. For the time period 1984 to 1999, the MCR was used
to determine the vital status if the information in the MCR
and the chart review was inconsistent (12 out of 845 pa-
tients). For 328 patients there was either no tumour stage
information and/or they received no treatment: 264
patients had no tumour stage information; 53 patients
had no treatment records and it was not possible to
identify whether they did or did not receive any treat-
ment; for 11 patients neither FIGO stage nor treatment
records were available. The final study sample con-
sisted of 1085 (77 %) cervical cancer cases. There were
no differences in demographic and clinical characteris-
tics for those included and not included in the analysis
(results not shown).
Treatment recommendations in the guidelines
As there are no published national guidelines for cervical
cancer treatment in Canada, synthesised guidelines were
derived from available provincial (published 2002
onwards) and international (FIGO) consensus and
evidence-based treatment guidelines. Although changes
occurred over time, there were no substantial differences
identified between the provincial and the FIGO guide-
lines. For the purpose of the analysis, the FIGO guidelines
were used as reference to evaluate the clinical practice in
Manitoba for the years 1984 to 1998 [12, 19]. For 1999 to
2008, the synthesised evidence-based guidelines were used
(Table 1) [4–7, 11]. It was not possible to determine if the
course of the treatment was completed or if the treat-
ment schedule/doses were modified due to intolerance
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or choices by physicians and/or patients, due to data
availability. Similarly, the exact timing and mecha-
nisms for the guideline implementation in the local
setting were not available from the administrative data.
Statistical analysis
The overall trend in the initial treatment during 1984
and 2008 was described using the 3-year average (Fig. 1).
Treatment patterns for cervical cancer patients by
diagnosis period (1984–1998, 1999–2008) stratified by
tumour stage (IA, IB-IIA, IIB-IVA and IVB) were
cross-tabulated. Bivariable analyses were conducted to
examine differences in demographic and tumour char-
acteristics of women who did and did not receive treat-
ment recommended in the guidelines.
A binomial logistic regression model was fitted to
identify the factors associated with receiving guideline
treatment (i.e., treatment according to the guidelines).
Factors examined included tumour stage; age at diag-
nosis (0-45 years, 46–65 years, >65 years); diagnosis
period (1984–1998, 1999–2008); histology (squamous
cell carcinoma or adenosquamous carcinoma, adeno-
carcinoma or other histology); and area of residence
(urban [Winnipeg and Brandon], rural).
A Cox proportional hazards regression model was used
to examine the association between receiving the treat-
ments as recommended and the risk of death from all
causes and from cervical cancer. Time to death was calcu-
lated from the date of diagnosis to the date of death or cen-
sored at 30 June 2010. Potential confounders included
diagnosis period, age, histology, area of residence and
tumour stage. Stratified analysis by tumour stage was also
performed. Data were analysed using SAS 9.2 (SAS Insti-
tute Inc., Cary, NC, USA).
Ethics approval
The study obtained human research ethics approval
from the University of Manitoba Health Research Ethics
Boards, the University of Sydney Human Research Ethics
Committee and Cancer Council NSW Human Research
Ethics Committee. As this study used de-identified data,
all Human Research Ethics Committees waived the need
for consent to participate in this study.
Results
Baseline characteristics
The median age at diagnosis of invasive cervical cancer
was 50 years (range: 16–89). The majority (74 %) of pa-
tients were diagnosed with either stage IB to IIA or IIB
to IVA disease. The proportion of women over 65 years
of age was greater in those diagnosed with stage IIB-IVB
disease than those with stage IA-IIA disease (32 % and
14 %, respectively). The majority of patients lived in
urban areas at the time of diagnosis (65 %). Squamous
cell carcinoma (including adenosquamous carcinoma)
was the most common histology type (80 %) (Table 2).
Surgery alone was the most frequently used treatment
for patients with IA and IB-IIA stage disease (93 % and
44 %, respectively), whereas radiotherapy alone was the
most frequently used therapy for patients with IIB-IVA
and IVB stage disease (60 % and 73 %, respectively)
(Table 3).
Table 1 Synthesised guidelines for treatment of cervical cancer cases
Recommended treatment
FIGO stage Consensus guidelinesa [12, 19] (applicable to 1998) Synthesised evidence-based guidelines [4–7, 11] (applicable from
1999 onwards)
IA1 Total hysterectomy, conisation, radical hysterectomyb,
radiotherapyc
Total hysterectomy, conisation, radiotherapy
IA2 Radical hysterectomy, total hysterectomy, radiotherapyc Radical hysterectomy, total hysterectomyd, trachelectomy,
radiotherapyc
IB-IIA
≤4 cm Radical hysterectomy, radiotherapy Radical hysterectomy, radiotherapy,
Radical hysterectomy + adjuvant radiotherapy (chemo-radiotherapy)
>4 cm Radical hysterectomy, radical hysterectomy + adjuvant
radiotherapy
Radical hysterectomy, chemo-radiotherapy,
Radical hysterectomy + adjuvant radiotherapy(chemo-radiotherapy)
IIB-IVA Chemo-radiotherapy, radiotherapy Chemo-radiotherapy
IVB Radiotherapy (curative/palliative), chemotherapy Radiotherapy (curative/palliative), chemotherapy, chemo-radiotherapy
aDevelopment of consensus guidelines is a long process and we assumed that the evidence supporting the decision was available before the guidelines were
published. Therefore, we measured concordance up to 1998 based on consensus guidelines published up to 2000
bRadical hysterectomy was used if there was lymph-vascular permeation on the cone biopsy
cRadiotherapy was used if medically inoperable
dTotal hysterectomy was used if there was no lympho-vascular permeation on the cone biopsy
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Overall trends in the initial treatment
During the period 1984 to 2008, use of chemo-radiotherapy
increased with a concomitant decrease in the use of radio-
therapy alone, especially for patients with tumour staged
IB2-IVA (Fig. 1). Until 1995, the predominant initial treat-
ment (i.e., treatment given within the first year after diagno-
sis) for stage IB2-IVA tumours was radiotherapy alone. The
use of combined chemo-radiotherapy started to increase
steadily from 4 % in 1993–1995 and became the predomin-
ant treatment from 1999 onward (67 % of women).
Guideline treatment
Most women with invasive cervical cancer in Manitoba
received guideline treatment (79 %, 95 % CI: 76–81 %)
over the study period. The overall proportion of women
receiving guideline treatment was higher in 1984–1998
(83 %, 95 % CI: 80–85 %) than in 1999–2008 (70 %, 95 %
CI: 65–75 %). The proportion of women receiving guideline
treatment by tumour stage in the later period did not
substantially differ from that in the earlier period, with the
exception of stage IIB-IVA (92 % vs 64 %) where a subs-
tantial proportion of women received radiotherapy alone
instead of chemo-radiotherapy in the later period (Table 3).
The bivariable analysis showed an association between
receipt of treatment according to the guidelines and
tumour stage (p = 0.005), tumour histology (p = 0.04)
and time period (p < 0.0001) (Table 2). The effect of time
period on the odds of receiving guideline treatment was
modified by both stage (p = 0.002) and age at diagnosis
(p < 0.0001) (Table 4). Compared with those who were
diagnosed in 1984–1998, patients diagnosed with stage
IA or IB-IIA tumours in 1999–2008 at over 65 years of
Fig. 1 Trends in the initial treatment for cervical cancer patients diagnosed with stage IB2-IVA tumours (n = 513). Other treatment includes surgery
alone, chemotherapy alone, pre-operative radiation followed by surgery, surgery with adjuvant chemotherapy, surgery with adjuvant radiotherapy,
palliative radiation and no treatment
Table 2 Characteristics of cervical cancer cases diagnosed in
1984–2008 by adherence to treatment guidelines (n = 1085a)





Characteristics No. (Column %) No. (Row %) No. (Row %) p-value*
Tumour stage 0.005
IA 230 (21) 175 (76) 55 (24)
IB-IIA 400 (37) 301 (75) 99 (25)
IIB-IVA 435 (37) 326 (75) 109 (25)
IVB 52 (5) 50 (96) 2 (4)
Age at diagnosis 0.22
0–45 518 (48) 398 (77) 120 (23)
46–65 333 (31) 261 (78) 72 (22)
>65 234 (22) 193 (82) 41 (18)
Histology 0.04
SCC 866 (80) 691 (80) 175 (20)




Urban 707 (65) 554 (78) 153 (22)
Rural 378 (35) 298 (79) 80 (21)
Diagnosis period <.0001
1984–1998 718 (66) 594 (83) 124 (17)
1999–2008 367 (34) 258 (70) 109 (30)
SCC squamous cell carcinoma/adenosquamous carcinoma
*For chi-square test of association
aAfter excluding cases with either missing stage data (14 %, mostly diagnosed
in 2000–2003), cause of death (4 %) or treatment records (5 %)
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Table 3 Treatment administered to cervical cancer cases by tumour stage and time period (1984–1998 and 1999–2008) (n = 1085)
Women treated for cervical cancer according to the guidelines by tumour stage and time period
Stage IAa (n = 229) Stage IB-IIAb (n = 398) Stage IIB-IVAc (n = 406) Stage IVB (n = 52)
1984–1998 1999–2008 1984–1998 1999–2008 1984–1998 1999–2008 1984–1998 1999–2008
Treatment No./Total % No./Total % No./Total % No./Total % No./Total % No./Total % No./Total % No./Total %
Surgery alone 121/152 80 46/62 74 95/138 69 32/36 89 0/3 0 0/2 0 0/0 - 0/0 -
Surgery + adjuvant radiotherapy 0/7 0 0/0 - 32/44 73 8/14 57 0/2 0 0/9 0 0/0 - 0/1 0
Preoperative radiotherapy + surgery 0/0 - 0/0 - 5/7 71 0/2 0 0/14 0 0/0 - 0/0 - 0/0 -
Surgery + adjuvant chemotherapy 0/0 - 0/0 - 0/2 0 0/0 - 0/0 - 0/0 - 0/0 - 0/1 0
Radiotherapy alone 7/7 100 1/1 100 99/99 100 8/9 89 196/196 100 0/49 0 17/17 100 21/21 100
Chemo-radiotherapy 0/0 - 0/0 - 0/6 0 22/38 58 22/22 100 108/108 100 0/0 - 10/10 100
Chemotherapy alone 0/0 - 0/0 - 0/2 0 0/1 0 0/0 - 0/1 0 0/0 - 2/2 100
Total 128/166 77 47/63 75 231/298 78 70/100 70 218/237 92 108/169 64 17/17 100 33/35 94
% (95 % CI) of women treated according to the guidelines
By tumour stage and time period 77 % (70–83 %) 75 % (62–85 %) 78 % (72–82 %) 70 % (60–79 %) 92 % (88–95 %) 64 % (56–71 %) 100 % (80–100 %) 94 % (81–99 %)
By tumour stage in 1984-2008 76 % (70–82 %) in 1984–2008 76 % (71–80 %) in 1984–2008 80 % (76–84 %) in 1984–2008 96 % (87–100 %) in 1984–2008
By time period for all tumour stages 83 % (80–85 %) in 1984–1998, 70 % (65–75 %) in 1999–2008
Overall 79 % (76–81 %) in 1984–2008
No. number of women treated according to the guidelines
aMost patients who did not receive guideline treatment were treated with different surgery types (for example, LEEP with or without hysterectomy or total hysterectomy where radical hysterectomy was indicated or
vice versa)
bMost patients who were not treated according to the guidelines were treated with total hysterectomy with or without adjuvant radiotherapy. Patients with bulky lesion and treated with chemo-radiotherapy were
regarded as not receiving guideline treatment











age were significantly less likely to receive treatment ac-
cording to the guidelines (OR = 0.11 in both stage
groups). For patients diagnosed with stage IIB-IVA disease
in the later period, women in all age groups were less likely
to receive treatment according to the guidelines compared
with those who were diagnosed in the earlier period.
Effect of guideline treatment on survival
The median follow-up time after diagnosis was 6.4 years
(range: 0.05–26.50 years). The overall number of deaths
due to cervical cancer and all causes was 312 and 473,
respectively. Among patients diagnosed with stage IA dis-
ease and who were not treated according to the guidelines,
there were no deaths from cervical cancer. Therefore,
cervical cancer death probabilities were determined for
those diagnosed with stage IB-IVB tumours only.
All-cause mortality
The risk of dying from any cause following a cervical
cancer diagnosis increased with the stage of the disease
and with increasing age at diagnosis (p < 0.0001)
(Table 5). The effect of being treated according to the
guidelines on all-cause mortality differed over the diag-
nosis period (Pinteraction = 0.0001). Patients diagnosed
in 1984–1998 and who were treated according to the
guidelines had a similar risk of dying to those who did
not (HR = 1.22, 95 % CI: 0.85–1.75). By contrast, women
diagnosed 1999–2008 and who were treated according to
the guidelines experienced a 56 % decreased risk of death
from all causes (HR = 0.44, 95 % CI: 0.31–0.64). Histology
(p = 0.47) and area of residence (p = 0.06) were not signifi-
cantly associated with the risk of dying from all causes. The
tumour stage stratified analysis (Table 6) showed that inde-
pendent effects of being treated according to the guidelines
Table 4 Factors associated with the probability of being treated according to treatment guidelines for cervical cancer cases
diagnosed in 1984–2008 (n = 1033)
Total no. cases Adjusted OR (95 % CI)a p-value
Histology 0.09
SCC 854 1.00
Others 211 0.72 (0.50–1.05)
Area of residence 0.77
Urban 691 1.00
Rural 374 0.95 (0.69–1.32)
Tumour stageb by time period and age at diagnosis
IA 0–45 years* 1984–1998** 119 1.00
1999–2008 50 0.99 (0.49–1.99)
46–65 years 1984–1998 35 1.00
1999–2008 11 0.97 (0.40–2.37)
>65 years 1984–1998 13 1.00
1999–2008 2 0.11 (0.04–0.33)
IB–IIA 0–45 years 1984–1998 172 1.00
1999–2008 50 1.04 (0.57–1.90)
46–65 years 1984–1998 72 1.00
1999–2008 31 1.02 (0.50–2.08)
>65 years 1984–1998 56 1.00
1999–2008 19 0.11 (0.04–0.29)
IIB–IVA 0–45 years 1984–1998 65 1.00
1999–2008 57 0.28 (0.13–0.57)
46–65 years 1984–1998 96 1.00
1999–2008 72 0.27 (0.14–0.54)
>65 years 1984–1998 104 1.00
1999–2008 41 0.03 (0.01–0.08)
OR odds ratio, SCC squamous cell carcinoma/adenosquamous carcinoma
*Interaction between time period and age (p < 0.0001)
**Interaction between time period and tumour stage (p = 0.002)
aOR was adjusted for all variables shown in this table
bPatients with tumour stage IVB were not included in the analysis due to insufficient number
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as well as being diagnosed in the later period, were only
observed for stage IIB-IVA disease, i.e., women who re-
ceived concurrent chemo-radiotherapy had a significantly
decreased risk of death from all causes (HR = 0.60, 95 % CI:
0.43–0.82, p = 0.002).
Cause-specific death
The risk of death from cervical cancer increased with
tumour stage at diagnosis (p < 0.0001) and in women
diagnosed over 65 years of age (p = 0.01) (Table 5).
The effect of the adherence to the guidelines was
found to be weakly modified by diagnosis period
(Pinteraction = 0.06). For those diagnosed in 1984–1998,
adherence to treatment guidelines did not impact the
probability of dying from cervical cancer (HR = 0.90,
95 % CI: 0.59–1.39) (Table 5). By contrast, women
diagnosed in 1999–2008 and who were treated ac-
cording to the guidelines had a reduced risk of dying
from cervical cancer (HR = 0.51, 95 % CI: 0.34–0.78).
The tumour stage stratified analysis showed independent
effects of receiving treatment according to the guide-
lines, and time period in those with stage IIB-IVA
disease (Table 6). Women with stage IIB-IVA disease
who received concurrent chemo-radiotherapy, had a
significantly decreased risk of death from cervical
cancer (HR = 0.64, 95 % CI: 0.44–0.93, p = 0.02).
Discussion
Brief summary of the main results
A shift from radiotherapy alone to concurrent chemo-
radiotherapy as the predominant treatment for IB2-IVA
stage cervical cancer cases was observed since 1999 in
Manitoba, Canada, which was concordant with the
changes in the published treatment guidelines [4–7, 11].
The likelihood of receiving the guideline treatment, as
well as the effect of guideline treatment on survival, var-
ied by diagnosis period and tumour stage. Women diag-
nosed with stage IIB-IVA disease since 1999 were less
likely to receive guideline treatment compared with
those diagnosed earlier. This finding may to be due, in
part, to older women not receiving concurrent chemo-
radiotherapy because of the presence of comorbidities,
poorer health or choice. The significant reduction in the
risk of death from both all causes (56 %) and from
Table 5 Association between receipt of guideline treatment and the probability of dying for cervical cancer patients (all stage groups)
who were diagnosed 1984–2008 (n= 1085)
Any death Death from cervical cancer
No. of death/Total Adjusted HR (95 % CI)a p-value No. of death/Total Adjusted HR (95 % CI)a p-value
Tumour stage <.0001 <.0001
IAb 23/229 1.00 1/229 -
IB-IIA 139/398 3.47 (2.22–5.41) 80/398 1.00
IIB-IVA 261/406 8.38 (5.39–13.03) 185/406 3.13 (2.36–4.15)
IVB 50/52 68.09 (39.38–117.74) 46/52 25.60 (16.61–39.46)
Age at diagnosis <.0001 0.01
0–45 127/518 1.00 99/518 1.00
46–65 165/333 1.69 (1.33–2.14) 106/333 1.12 (0.85–1.49)
>65 181/234 2.64 (2.07–3.37) 107/234 1.52 (1.14–2.03)
Histology 0.47 0.08
SCC 378/866 1.00 240/866 1.00
Others 95/219 1.09 (0.86–1.38) 72/219 1.28 (0.97–1.68)
Area of residence 0.06 0.50
Urban 292/707 1.00 196/707
Rural 181/378 1.20 (0.99–1.44) 116/378 1.08 (0.86–1.37)
Time period* 0.0001 0.06
1984–1998 No receipt 35/124 1.00 25/124 1.00
Receipt 298/594 1.22 (0.85–1.75) 172/594 0.90 (0.59–1.39)
1999–2008 No receipt 51/109 1.00 37/109 1.00
Receipt 89/258 0.44 (0.31–0.64) 78/258 0.51 (0.34–0.78)
HR hazard ratio, SCC squamous cell carcinoma/adenosquamous carcinoma, No receipt did not receive guideline treatment, Receipt Received guideline treatment
*p-value for interaction between time period and treatment according to the guidelines
aHR was adjusted for all variables shown in this table
bHR for patients with tumour stage IA was not considered since none died from cervical cancer in the group who were not treated according to the guidelines
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cervical cancer (49 %) was observed only in those who
were diagnosed since 1999 and received guideline treat-
ment, and this appeared to be largely driven by the use of
concurrent chemo-radiotherapy in stage group IIB-IVA.
Explanation for the findings
Previous studies reported a rapid increase in the use of
concurrent chemo-radiotherapy following the USA
National Cancer Institute’s clinical announcement in
1999, which strongly encouraged cisplatinum-based
concurrent chemo-radiotherapy for advanced stage
cervical cancer [13, 14]. However, the current study
observed that the change in management practice was
already occurring while the related RCTs were being
conducted. This implies that clinicians could have been
aware of the trials from scientific meetings before the
results were published in peer reviewed journals, and were
ready to adopt the new evidence into the management of
advanced cervical cancer. A similar phenomenon has been
reported in the treatment of other cancer types, for ex-
ample in the use of taxanes for primary breast cancer. The
use of Paclitaxel substantially increased in the year follow-
ing the presentation of study findings at the American
Society of Clinical Oncology (ASCO) meeting in 1998, but
the study was not published in a peer reviewed journal until
five years later [20].
In agreement with previous reports, this study also found
that older women were less likely to receive concurrent
Table 6 Effects of being treated according to the guidelines and time period on the probability of dying from all causes and
cervical cancer by tumour stage (n = 1085)
Any death Death from cervical cancer
No. of death/Total Adjusted HR (95 % CI)a p-value No. of death/Total Adjusted HR (95 % CI)a p-value
Stage IAb
Treated according to guidelines
No 1/54 1.00 0.08 0/54 -
Yes 22/175 5.98 (0.80–44.83) 1/175
Time period
1984–1998 22/166 1.00 0.41 1/166 -
1999–2008 1/63 0.42 (0.05–3.28) 0/63
Stage IB-IIA
Treated according to guidelines
No 29/97 1.00 0.84 19/97 1.00 0.43
Yes 110/301 0.96 (0.63–1.47) 61/301 0.81 (0.48–1.38)
Time period
1984–1998 116/298 1.00 0.50 64/298 1.00 0.45
1999–2008 23/100 0.85 (0.53–1.37) 16/100 0.80 (0.45–1.43)
Stage IIB-IVA
Treated according to guidelines
No 54/80 1.00 0.002 41/80 1.00 0.02
Yes 207/326 0.60 (0.43–0.82) 144/326 0.64 (0.44–0.93)
Time period
1984–1998 178/237 1.00 0.004 115/237 1.00 0.04
1999–2008 83/169 0.65 (0.48–0.87) 70/169 0.71 (0.51–0.98)
Stage IVB
Treated according to guidelines
No 2/2 1.00 0.63 2/2 1.00 0.55
Yes 48/50 0.68 (0.14–3.30) 44/50 0.62 (0.13–3.02)
Time period
1984–1998 17/17 1.00 0.03 17/17 1.00 0.02
1999–2008 33/35 0.43 (0.20–0.93) 29/35 0.38 (0.17–0.84)
aHR was adjusted for age at diagnosis, histology, area of residence, time period and treatment according to the guidelines
bThe HR for patients diagnosed with tumours stage IA patients was not calculated because there were no deaths from cervical cancer
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chemo-radiotherapy [13, 21]. Chemo-radiotherapy is asso-
ciated with acute haematological, renal and gastrointestinal
toxicity [22]. Therefore, patients with poor performance
status and co-morbid conditions received radiotherapy
alone [13]. The main reason for patients not receiving
chemo-radiotherapy in Manitoba was poor renal function
at diagnosis (Personal communication, Dr Robert Lotocki,
CancerCare Manitoba, Canada), although detailed informa-
tion was not available to adjust for treatment uptake and
survival in the current analysis.
The improved survival found in this study could po-
tentially have resulted from a range of factors, including
the use of concurrent chemo-radiotherapy as well as
instituting a policy of maintaining a patient’s haemoglo-
bin to greater than 120 g/L using blood transfusion
while on treatment [23]. Studies from two Canadian
centres in Ontario have investigated trends in the use
of concurrent chemo-radiotherapy and the resulting
improved survival outcomes, although they have not
included stage-specific analyses [13, 14]. An American
study reported that patients who did not receive guide-
line treatment experienced similar survival to those
who did in 1988–1994 [24]. In the current study,
women who were treated according to the guidelines
in 1984 and 1998 experienced the same risk of death as
those who were not treated according to the guide-
lines. By contrast, a significant reduction in the risk of
dying from all causes and from cervical cancer was
observed in those who received guideline treatment
from 1999 onwards. In the stratified analysis by stage,
the decreased all cause and cervical cancer mortality
associated with receiving recommended concurrent
chemo-radiotherapy was confined to patients with stage
IIB-IVA disease (40 % and 36 %, respectively), which was
consistent with the relevant clinical trials and the previous
studies [1–3, 21, 25–27]. The contributing effects of other
treatments (such as maintenance of haemoglobin levels),
which was not assessable in the current dataset, cannot be
excluded.
Strengths
This is the first population-based study of cervical cancer
treatment in relation to the changes in the treatment guide-
lines both in Canada and internationally, which adjusted for
potential confounders including tumour stage. The follow-
up time in this study was longer than that previously re-
ported in other studies with an overall median follow up
time of 6.4 years [25].
Limitations
Similar to other population-based studies using administra-
tive data [14, 25], this study has some limitations related to
data availability. Therefore, we could only assess broad
concordance with guidelines and could not take into
account individual patient factors, specifically the ef-
fects of co-morbidities, poor performance status and
patients’ treatment preferences. Similarly, we could not
assess other underlying factors related to practice that
deviated from the guidelines, such as clinician referral
practice, limitations in health care access and patient
compliance. Accordingly, we are unsure to what extent
each of these non-assessable factors contributed to the
suboptimal treatment patterns observed. This is an
area for future research if information on patients’ co-
morbidity and performance status, such as the Eastern
Cooperative Oncology Group (ECOG) score, is routinely
recorded in the clinical charts. About 20 % of cervical
cancer patients diagnosed during the study period in
Manitoba did not have their tumour stage recorded,
and therefore were not included in the analysis. Miss-
ing stage information for these patients may have had
an effect on the overall treatment patterns in accord-
ance with the guidelines. Nevertheless, the extensive
record linkage system in Manitoba allowed us to obtain
demographic information for all patients as well as detailed
information on treatment and stage for the majority (77 %)
of cervical cancer cases over a long period of time, and we
were thereby able to examine the effect of guideline-
recommended treatment on survival after adjusting for
confounding effects due to age and stage of disease.
Conclusions
Consistent evidence from clinical trials investigating the
survival benefit of concurrent chemo-radiotherapy on
cervical cancer led to substantial revision of treatment
guidelines. We found this resulted in a rapid increase in
the use of concurrent chemo-radiotherapy and an associ-
ated significantly increased survival in women diagnosed
with invasive stage IIB-IVA cervical cancer, although the
effect of other changes in clinical practice on increased
survival cannot be ruled out.
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